RAD52 Variants Predict Platinum Resistance and Prognosis of Cervical Cancer

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Shi, Ting Yan ^a,d   Yang, Gong ^a   Tu, Xiao Yu ^a   Yang, Jing Min ^b   Qian, Ji ^b   Wu, Xiao Hua ^a   Zhou, Xiao Yan ^a   Cheng, Xi ^a   Wei, Qingyi ^a,c  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d SHANGHAI INSTITUTE OF PLANNED PARENTHOOD RESEARCH   (China)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CARBOPLATIN; CISPLATIN; NEDAPLATIN; OXALIPLATIN; PLATINUM COMPLEX; RAD52 PROTEIN;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER SURGERY; CANCER SURVIVAL; CELL ASSAY; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; GENE FREQUENCY; GENE FUNCTION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MAJOR CLINICAL STUDY; PREDICTION; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RAD52 GENE; SINGLE NUCLEOTIDE POLYMORPHISM; UTERINE CERVIX CARCINOMA;

ADULT; AGED; CARBOPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; GENOTYPE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MODELS, STATISTICAL; ORGANOPLATINUM COMPOUNDS; POLYMORPHISM, SINGLE NUCLEOTIDE; RAD52 DNA REPAIR AND RECOMBINATION PROTEIN; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84870565379     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0050461     Document Type: Article

References (41)

1. Jemal A, Bray F, (2011) Center MM, Ferlay J, Ward E, et al (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
2. Lissoni AA, Colombo N, Pellegrino A, Parma G, Zola P, et al. (2009) A phase II, randomized trial of neo-adjuvant chemotherapy comparing a three-drug combination of paclitaxel, ifosfamide, and cisplatin (TIP) versus paclitaxel and cisplatin (TP) followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the Snap-02 Italian Collaborative Study. Ann Oncol 20: 660-665.
3. Dubay RA, Rose PG, O'Malley DM, Shalodi AD, Ludin A, et al. (2004) Evaluation of concurrent and adjuvant carboplatin with radiation therapy for locally advanced cervical cancer. Gynecol Oncol 94: 121-124.
4. Cadron I, Van Gorp T, Amant F, Leunen K, Neven P, et al. (2007) Chemotherapy for recurrent cervical cancer. Gynecol Oncol 107: S113-S118.
5. Burger H, Loos WJ, Eechoute K, Verweij J, Mathijssen RH, et al. (2011) Drug transporters of platinum-based anticancer agents and their clinical significance. Drug Resist Updat 14: 22-34.
6. Watari H, Kanuma T, Ohta Y, Hassan MK, Mitamura T, et al. (2010) Clusterin expression inversely correlates with chemosensitivity and predicts poor survival in patients with locally advanced cervical cancer treated with cisplatin-based neoadjuvant chemotherapy and radical hysterectomy. Pathol Oncol Res 16: 345-352.
7. Koberle B, Tomicic MT, Usanova S, Kaina B, (2010) Cisplatin resistance: preclinical findings and clinical implications. Biochim Biophys Acta 1806: 172-182.
8. Rabik CA, Dolan ME, (2007) Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 33: 9-23.
9. Ishino Y, Nishino T, Morikawa K, (2006) Mechanisms of maintaining genetic stability by homologous recombination. Chem Rev 106: 324-339.
10. Li F, Sun X, Sun N, Qin S, Cheng H, et al. (2010) Association between polymorphisms of ERCC1 and XPD and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer. Am J Clin Oncol 33: 489-494.
11. Li D, Zhou Q, Liu Y, Yang Y, Li Q, (2011) DNA repair gene polymorphism associated with sensitivity of lung cancer to therapy. Med Oncol 29: 1266-1268.
12. Brozovic A, Damrot J, Tsaryk R, Helbig L, Nikolova T, et al. (2009) Cisplatin sensitivity is related to late DNA damage processing and checkpoint control rather than to the early DNA damage response. Mutat Res 670: 32-41.
13. Xu ZY, Loignon M, Han FY, Panasci L, Aloyz R, (2005) Xrcc3 induces cisplatin resistance by stimulation of Rad51-related recombinational repair, S-phase checkpoint activation, and reduced apoptosis. J Pharmacol Exp Ther 314: 495-505.
14. Mortensen UH, Bendixen C, Sunjevaric I, Rothstein R, (1996) DNA strand annealing is promoted by the yeast Rad52 protein. Proc Natl Acad Sci U S A 93: 10729-10734.
15. Tassone P, Di Martino MT, Ventura M, Pietragalla A, Cucinotto I, et al. (2009) Loss of BRCA1 function increases the antitumor activity of cisplatin against human breast cancer xenografts in vivo. Cancer Biol Ther 8: 648-653.
16. Kim K, Kang SB, Chung HH, Kim JW, Park NH, et al. (2008) XRCC1 Arginine194Tryptophan and GGH-401Cytosine/Thymine polymorphisms are associated with response to platinum-based neoadjuvant chemotherapy in cervical cancer. Gynecol Oncol 111: 509-515.
17. Yin M, Yan J, Martinez-Balibrea E, Graziano F, Lenz HJ, et al. (2011) ERCC1 and ERCC2 polymorphisms predict clinical outcomes of oxaliplatin-based chemotherapies in gastric and colorectal cancer: a systemic review and meta-analysis. Clin Cancer Res 17: 1632-1640.
18. Siraj AK, Al-Rasheed M, Ibrahim M, Siddiqui K, Al-Dayel F, et al. (2008) RAD52 polymorphisms contribute to the development of papillary thyroid cancer susceptibility in Middle Eastern population. J Endocrinol Invest 31: 893-899.
19. Beesley J, Jordan SJ, Spurdle AB, Song H, Ramus SJ, et al. (2007) Association between single-nucleotide polymorphisms in hormone metabolism and DNA repair genes and epithelial ovarian cancer: results from two Australian studies and an additional validation set. Cancer Epidemiol Biomarkers Prev 16: 2557-2565.
20. Yamaue H, Tanimura H, Tsunoda T, Tani M, Iwahashi M, et al. (1991) Chemosensitivity testing with highly purified fresh human tumour cells with the MTT colorimetric assay. Eur J Cancer 27: 1258-1263.
21. LI J, Liu C, An H, (2006) Determination of Cisplatin in Human Plasma by HPLC (in Chinese). China Pharmacy 17: 1399-1400.
22. Sasaki Y, Tamura T, Eguchi K, Shinkai T, Fujiwara Y, et al. (1989) Pharmacokinetics of (glycolate-0,0′)-diammine platinum (II), a new platinum derivative, in comparison with cisplatin and carboplatin. Cancer Chemother Pharmacol 23: 243-246.
23. Kawanishi K, Miyagi Y, Yamamoto J, Miyagi Y, Nakamura K, et al. (2001) Cytocidal effect and DNA damage of nedaplatin in vitro by simulating pharmacokinetic parameters. Cancer Chemother Pharmacol 47: 303-308.
24. Morrison JG, White P, McDougall S, Firth JW, Woolfrey SG, et al. (2000) Validation of a highly sensitive ICP-MS method for the determination of platinum in biofluids: application to clinical pharmacokinetic studies with oxaliplatin. J Pharm Biomed Anal 24: 1-10.
25. Scheithauer W, Clark GM, Salmon SE, Dorda W, Shoemaker RH, et al. (1986) Model for estimation of clinically achievable plasma concentrations for investigational anticancer drugs in man. Cancer Treat Rep 70: 1379-1382.
26. Yamaue H, Tanimura H, Noguchi K, Hotta T, Tani M, et al. (1992) Chemosensitivity testing of fresh human gastric cancer with highly purified tumor cells using the MTT assay. Br J Cancer 66: 794-799.
27. Cheng X, Yang G, Schmeler KM, Coleman RL, Tu X, et al. (2011) Recurrence patterns and prognosis of endometrial stromal sarcoma and the potential of tyrosine kinase-inhibiting therapy. Gynecol Oncol 121: 323-327.
28. Koshiyama M, Fujii H, Kinezaki M, Morita Y, Nanno H, et al. (2001) Immunohistochemical expression of topoisomerase IIalpha (Topo IIalpha) and multidrug resistance-associated protein (MRP), plus chemosensitivity testing, as chemotherapeutic indices of ovarian and endometrial carcinomas. Anticancer Res 21: 2925-2932.
29. Koshiyama M, Kinezaki M, Uchida T, Sumitomo M, (2005) Chemosensitivity testing of a novel platinum analog, nedaplatin (254-S), in human gynecological carcinomas: a comparison with cisplatin. Anticancer Res 25: 4499-4502.
30. Park JS, Jeon EK, Chun SH, Won HS, Lee A, et al. (2011) ERCC1 (excision repair cross-complementation group 1) expression as a predictor for response of neoadjuvant chemotherapy for FIGO stage 2B uterine cervix cancer. Gynecol Oncol 120: 275-279.
31. Wang H, Zhang SY, Wang S, Lu J, Wu W, et al. (2009) REV3L confers chemoresistance to cisplatin in human gliomas: the potential of its RNAi for synergistic therapy. Neuro Oncol 11: 790-802.
32. Khanna KK, Jackson SP, (2001) DNA double-strand breaks: signaling, repair and the cancer connection. Nat Genet 27: 247-254.
33. Brozovic A, Damrot J, Tsaryk R, Helbig L, Nikolova T, et al. (2009) Cisplatin sensitivity is related to late DNA damage processing and checkpoint control rather than to the early DNA damage response. Mutat Res 670: 32-41.
34. Frit P, Canitrot Y, Muller C, Foray N, Calsou P, et al. (1999) Cross-resistance to ionizing radiation in a murine leukemic cell line resistant to cis-dichlorodiammineplatinum(II): role of Ku autoantigen. Mol Pharmacol 56: 141-146.
35. Lettier G, Feng Q, de Mayolo AA, Erdeniz N, Reid RJ, et al. (2006) The role of DNA double-strand breaks in spontaneous homologous recombination in S. cerevisiae. PLoS Genet 2: e194.
36. West SC, (2003) Molecular views of recombination proteins and their control. Nat Rev Mol Cell Biol 4: 435-445.
37. Feng Z, Scott SP, Bussen W, Sharma GG, Guo G, et al. (2011) Rad52 inactivation is synthetically lethal with BRCA2 deficiency. Proc Natl Acad Sci U S A 108: 686-691.
38. Koberle B, Tomicic MT, Usanova S, Kaina B, (2010) Cisplatin resistance: preclinical findings and clinical implications. Biochim Biophys Acta 1806: 172-182.
39. Kertesz M, Iovino N, Unnerstall U, Gaul U, Segal E, (2007) The role of site accessibility in microRNA target recognition. Nat Genet 39: 1278-1284.
40. MacQuarrie KL, Fong AP, Morse RH, Tapscott SJ, (2011) Genome-wide transcription factor binding: beyond direct target regulation. Trends Genet 27: 141-148.
41. Jewell R, Conway C, Mitra A, Randerson-Moor J, Lobo S, et al. (2010) Patterns of expression of DNA repair genes and relapse from melanoma. Clin Cancer Res 16: 5211-5221.